Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 7Active not recruiting 4Not yet recruiting 2Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 128Breast Neoplasms 111Neoplasms 93Neoplasm Metastasis 76Melanoma 70Colorectal Neoplasms 69Leukemia, Myeloid, Acute 66Prostatic Neoplasms 58Multiple Myeloma 53Lung Neoplasms 51Ovarian Neoplasms 49Squamous Cell Carcinoma of Head and Neck 45Recurrence 41Triple Negative Breast Neoplasms 40Carcinoma, Renal Cell 38Carcinoma, Hepatocellular 38Pancreatic Neoplasms 36Myelodysplastic Syndromes 36Glioblastoma 34Brain Neoplasms 34Stomach Neoplasms 30Lymphoma, Non-Hodgkin 30Lymphoma 30Endometrial Neoplasms 30Head and Neck Neoplasms 28Lymphoma, Large B-Cell, Diffuse 27Leukemia 27Uterine Cervical Neoplasms 26Cholangiocarcinoma 26Urinary Bladder Neoplasms 24

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sarcoma, Alveolar Soft Part × 1 year × Clear all
NCT02936102 2025-11-14

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1 Terminated
154 enrolled
BreastSarcoma

Chordoma, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡